Syngene International Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024
April 24, 2024 at 10:17 am
Share
Syngene International Limited reported earnings results for the fourth quarter and full year ended March 31, 2024. For the fourth quarter, the company reported sales was INR 9,169 million compared to INR 9,944 million a year ago. Revenue was INR 9,330 million compared to INR 10,172 million a year ago. Net income was INR 1,886 million compared to INR 1,787 million a year ago. Basic earnings per share from continuing operations was INR 4.7 compared to INR 4.46 a year ago. Diluted earnings per share from continuing operations was INR 4.69 compared to INR 4.43 a year ago.
For the full year, the company reported sales was INR 34,886 million compared to INR 31,929 million a year ago. Revenue was INR 35,792 million compared to INR 32,635 million a year ago. Net income was INR 5,100 million compared to INR 4,644 million a year ago. Basic earnings per share from continuing operations was INR 12.71 compared to INR 11.59 a year ago. Diluted earnings per share from continuing operations was INR 12.69 compared to INR 1,131 a year ago.
Syngene International Limited is an integrated research, development, and manufacturing services company. The Company is engaged in providing contract research and manufacturing services from lead generation to clinical supplies to pharmaceutical and biotechnology companies worldwide. Its services include drug discovery and development capabilities in medicinal chemistry, biology, in vivo pharmacology, toxicology, custom synthesis, process research and development, current good manufacturing practice (cGMP) manufacturing, formulation, and analytical development, along with clinical development services. It offers SynVent, a therapeutic discovery and development platform for executing drug discovery projects. SynVent's portfolio covers modalities and therapeutic areas ranging from small molecule inhibitors to targeted protein stabilization. It serves the pharmaceutical, biotechnology, and specialty chemical sectors, among others. It operates multi-modal biologics manufacturing facility.